End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 Summary Global Markets Direct's, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of route of administration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) '
Pipeline Review, H2 2012
Published on December 2012
Report Summary
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012
Summary
Global Markets Direct's, 'End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2012', provides an
overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for End-Stage
Kidney Disease (End-Stage Renal Disease or ESRD), complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for End-Stage Kidney Disease (End-Stage
Renal Disease or ESRD). End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, Half Year is built using
data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- A snapshot of the global therapeutic scenario for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD).
- A review of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) products under development by companies and
universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline on the basis of route of administration
and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage
Renal Disease or ESRD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 1/7

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 8
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Development by Companies 10
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Products under Development by Companies 16
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Products under Investigation by Universities/Institutes
17
Companies Involved in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics Development 18
Eli Lilly and Company 18
Isis Pharmaceuticals, Inc. 19
La Jolla Pharmaceutical Company 20
Hawthorn Pharmaceuticals, Inc. 21
Ardelyx, Inc. 22
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
tabalumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
benazepril hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 2/7

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
valsartan - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Benazepril + Valsartan - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Folate + Pyridoxine + Cyanocobalamin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Neo-Kidney Augment - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
haw Nuv-15 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
haw Nuv16 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
acetylcysteine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ISIS-CRPRx - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LJPC-101 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
spironolactone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RDX-013 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Drug Profile Updates 47
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Discontinued Products 50
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics - Dormant Products 51
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Product Development Milestones 52
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 3/7

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Featured News & Press Releases 52
Nov 05, 2012: Tengion Receives Notice Of Allowance For US Patent Application Covering Renal Regeneration For Neo-Kidney
Augment Product Candidate 52
Jul 31, 2012: La Jolla Pharma Announces FDA Agreement With Proposed Phase I Clinical Trial Of GCS-100 In Chronic Kidney
Disease 53
Jul 31, 2012: Rockwell Medical Completes Patient Enrollment In Phase III Clinical Trials For SFP Iron-Delivery In Hemodialysis
Patients 53
Jun 27, 2012: Rockwell Medical Receives Canadian Patent For SFP-Iron Delivery 53
Apr 30, 2012: Rockwell Medical Completes Patient Enrollment In PRIME Clinical Study 54
Mar 19, 2012: Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies To Continue as Planned
54
Dec 12, 2011: Rockwell Medical Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue As Planned 55
Nov 14, 2011: KAI Announces Results From Phase II study Of ONO-5163/KAI-4169, Calcium Sensing Receptor Agonist 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Number of Products Under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2012 8
Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Eli Lilly and Company, H2 2012 18
Isis Pharmaceuticals, Inc., H2 2012 19
La Jolla Pharmaceutical Company, H2 2012 20
Hawthorn Pharmaceuticals, Inc., H2 2012 21
Ardelyx, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Drug Profile Updates 47
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Discontinued Products 50
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Therapeutics ' Dormant Products 51
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 4/7

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2012 8
Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 5/7

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 000.00 Quantity: _____
Site License--USD 4 000.00 Quantity: _____
Corporate License--USD 6 000.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 6/7

7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) ' Pipeline Review, H2 2012 (From Slideshare) Page 7/7